ARA290 Attenuates Apical Periodontitis via SIRT1/NF-κB/IL-1β Pathway Modulation.
ARA290 may help reduce inflammation and bone loss in apical periodontitis by modulating specific signaling pathways, but further research is needed to confirm these effects in humans.
Where it sits
this study against the rest of the cibinetide corpusSummary and findings
This study investigated the effects of ARA290 on apical periodontitis (AP) in vivo and in vitro, focusing on the SIRT1/NF-κB/IL-1β signaling pathway. ARA290 treatment resulted in a significant reduction of inflammatory markers and bone loss associated with AP. The study aimed to elucidate the underlying mechanisms of ARA290's protective effects in AP models.
Abstract
<h4>Introduction and aims</h4>Existing research suggests that ARA290 may possess therapeutic potential for apical periodontitis (AP), although the mechanisms involved remain unclear. This study aims to investigate the protective effects and underlying mechanisms of ARA290 in mitigating pro-inflammatory responses of macrophages in the context of AP.<h4>Methods</h4>Initially, in vivo models of AP were used to assess the aberrant activation of the SIRT1/NF-κB/IL-1β signalling pathway within periapical lesions. Furthermore, the expression levels of the SIRT1/NF-κB/IL-1β signalling pathway in ARA290-treated AP models, both in vivo and in vitro, were evaluated using immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) techniques to elucidate the role of ARA290 in modulating this signalling pathway during AP pathogenesis. Subsequently, the SIRT1/NF-κB/IL-1β signalling pathway was inhibited using selisistat, and the resultant changes in inflammatory levels and bone resorption in periapical lesions were assessed through haematoxylin and eosin staining, tartrate-resistant acid phosphatase staining, IHC and micro-computed tomography (Micro CT).<h4>Results</h4>The in vivo AP model demonstrated a 50% reduction in SIRT1 expression within periapical lesions, accompanied by a 5-fold increase in the expression of acetylated NF-κB (p65) and IL-1β. Additionally, the administration of ARA290 in the AP mouse model significantly reduced inflammatory infiltration, the number of osteoclasts and the extent of bone loss in the periapical region. Notably, ARA290 treatment enhanced SIRT1 expression by approximately 40% while concurrently decreasing the levels of acetylated NF-κB (p65) by around 75% and IL-1β by approximately 62.5% in both in vivo and in vitro AP models. Importantly, inhibition of the SIRT1/NF-κB/IL-1β signalling pathway negated the beneficial effects of ARA290 in attenuating the progression of AP.<h4>Conclusions</h4>ARA290 plays a protective role by modulating the SIRT1/NF-κB/IL-1β signalling pathway in apical periodontitis, which may provide a new direction for the adjuvant treatment of apical periodontitis.
Background
This paper addresses the role of ARA290 in apical periodontitis (AP), a condition characterized by inflammation and bone loss around the tooth root. Previous research has indicated that ARA290 may have therapeutic potential, but the specific mechanisms by which it exerts its effects are not well understood. Understanding these mechanisms is crucial for developing effective treatments for AP.
Methods
The study utilized in vivo models of AP to assess the activation of the SIRT1/NF-κB/IL-1β signaling pathway. Various techniques, including immunohistochemistry, Western blotting, and immunofluorescence, were employed to evaluate expression levels in ARA290-treated models. The study also involved inhibiting the signaling pathway using selisistat to observe changes in inflammatory levels and bone resorption.
Results
The primary endpoint indicated a 50% reduction in SIRT1 expression within periapical lesions. Additionally, ARA290 treatment resulted in a 40% enhancement of SIRT1 expression, a 75% decrease in acetylated NF-κB (p65), and a 62.5% decrease in IL-1β levels. The administration of ARA290 also significantly reduced inflammatory infiltration and the number of osteoclasts.
Interpretation
The findings suggest that ARA290 may modulate the SIRT1/NF-κB/IL-1β signaling pathway, which aligns with previous literature indicating the importance of this pathway in inflammatory responses. However, the clinical significance of the observed changes, particularly the effect sizes, remains uncertain. Limitations such as the reliance on animal models and the absence of human data may confound the conclusions drawn from this study.
Key findings
- 50% reduction in SIRT1 expression within periapical lesions.
- 5-fold increase in the expression of acetylated NF-κB (p65) and IL-1β.
- ARA290 treatment enhanced SIRT1 expression by approximately 40%.
- Decreased levels of acetylated NF-κB (p65) by around 75%.
- Decreased IL-1β levels by approximately 62.5%.
Limitations
- animal models used, results may not translate to humans
- short follow-up period
- surrogate endpoints utilized
- single-site study